Cardinal Health (NYSE:CAH) Stock, Quote.Headers.trade-ideas

Cardinal Health

Cardinal Health is one of three leading pharmaceutical wholesalers in the us, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and McKesson, the three comprise well over 90% of the us pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Healthcare,,Opioid,Epidemic,And,Drug,Abuse,Concept,With,The,Map

Large Cap

News

Health Care

Legal

General

Three major U.S. drug distributors, McKesson, Cencora, and Cardinal Health, have agreed to a $300 million settlement over claims by health insurers and benefit plans that they contributed to the opioid epidemic.

Opioid Settlement: Drug Distributors McKesson, Cencora, Cardinal Health To Pay $300M To Health Insurers

Earnings

Guidance

Dividends

Price Target

Markets

Analyst Ratings

Trading Ideas

Cardinal Health Inc. (NYSE: CAH) is a global pharmaceutical and medical products distributor serving over 100,000 hospitals. It&#39;s also the largest distributor of medical supplies and surgical products in the United States.

Cardinal Health Soars as America&#39;s Leading Acute Care Supplier

cardinalhealth-Company

Cardinal Health Analysts Raise Their Forecasts Following Upbeat Earnings

Cardinal Health Inc

CARRIER ALLIANCE HLDGS by Carrier Alliance Holdings, Inc.

Carrier Alliance Holdings Inc

CELESTIAL ASIA SECS NEW by Celestial Asia Secs Holdings Ltd.

Celestial Asia Securities Holdings Ltd

Caro Holdings Inc

EVOLUTION MINING LTD ORD by Evolution Mining Ltd.

Evolution Mining Ltd

The three largest U.S. drug distributors have reached a settlement of $300 million to resolve claims from health insurers and benefit plans over their alleged role in fueling the opioid epidemic, according to court documents filed on Friday.
The settlement involves McKesson Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), Cencora Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>), and Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>). The proposed class action settlement, disclosed in a federal court in Cleveland, Ohio, requires a judge&#8217;s approval.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/06/39546645/unitedhealths-optumrx-settles-opioid-prescription-claims-for-20m" rel="noreferrer noopener">UnitedHealth&#8217;s OptumRx Settles Opioid Prescription Claims for $20M</a>.
Reuters highlights that the settlement comes on the heels of a $21 billion agreement by the same companies to settle claims from state and local governments.
Those claims accused the distributors of failing to implement proper controls, which allowed large quantities of addictive painkillers to be diverted into illegal markets.
The new settlement addresses the claims of third-party payers, such as union funds, who bore the financial burden of overprescribed and overmarketed opioid medications and the subsequent treatment of opioid use disorder.
The distributors did not admit any wrongdoing as part of the settlement. The $300 million payment will be divided among the companies, with McKesson paying 38.1%, Cardinal Health and Cencora paying 30.9% and 31%, respectively.
The case is part of a broader wave of litigation against drug manufacturers, distributors, and pharmacies, seeking accountability for a nationwide opioid crisis that has claimed hundreds of thousands of lives over the past two decades.
These lawsuits have collectively resulted in over $50 billion in settlements, primarily with state and local governments.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40691948/praxis-precision-medicines-touts-encouraging-data-for-mid-stage-epilepsy-drug" target="_blank" rel="noreferrer noopener">Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug</a>.</li>
</ul>
Image via Shutterstock

Cardinal Health Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cah#NYSE">CAH</a>) is a global pharmaceutical and medical products distributor serving over 100,000 hospitals. It&#39;s also the largest distributor of medical supplies and surgical products in the United States. Cardinal Health provides medical supplies and specialty therapeutics to 90% of the hospitals in the United States, as well as 60,000 pharmacies and over 10,000 specialty physician offices.
The rising trend in acute care utilization from emergency rooms, ambulatory and surgical care centers, and inpatient hospital visits has helped drive record results for the company. The stock is also a dividend aristocrat, having raised its dividend for nearly 40 consecutive years.
Cardinal Health operates in the medical sector with major healthcare services companies like McKesson Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mck#NYSE">MCK</a>), Stryker Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>), and Cencora Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cor#NYSE">COR</a>).
<h2>Cardinal Health&#39;s Massive Portfolio and Reach </h2>
The company&#39;s professional products range from durable medical equipment to anesthesia supplies, personal protective equipment (PPE), lab supplies, and surgical equipment. It carries over 46,000 home healthcare products to over 3.4 million patients. Its digital ecosystem supports medication adherence to over 23 million patients and over 60 payers. The company offers numerous tailored services, including data and analytics, to improve cost efficiencies, workflows, and waste reduction for ambulatory surgery centers, hospitals, pharmacies, and labs. They even provide customer packaging solutions to pharmaceuticals through its 60,000-square-foot facility with automated and semi-automated equipment accommodating small and large-volume batches and projects in compliance with all FDA standards.
<h2>Cardinal Health: Expanding Its Specialty Business </h2>
Cardinal continues to expand its specialty business, which focuses on distributing and servicing specialty pharmaceuticals, pharmacies, and physician practices. It offers technology platforms that help manage inventory, track patient outcomes, manage reimbursement cycles, and improve efficiency for pharmacies and practices. Specialty therapeutics include a wide array of high-cost, complex medications that often require special storage, handling, and patient support programs. In January 2024, the company agreed to acquire Specialty Networks for $1.2 billion in cash to accelerate growth in its Specialty business. &nbsp;
<img alt="Cardinal Health CAH stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20240818185626_chartb-cah.jpg" style="height:750px; width:915px" />
<h2>CAH Stocks Forms a Cup and Handle Breakout Pattern </h2>
The daily candlestick chart for CAH illustrates a cup and handle breakout pattern. The cup lip line at $105.08 was tested on Aug. 8, 2024. The pullback formed the handle staging the rally into its earnings release. CAH gapped to the cup lip line and proceeded to break out higher after testing the support for two days. The daily relative strength index (RSI) has bounced to the 75-band. Pullback support levels are at $105.08, $102.81, $98.79, and $96.05.
<h2>Cardinal Health Beats Top and Bottom Line Estimates </h2>
The fiscal fourth-quarter 2024 earnings report indicated strong top- and bottom-line acceleration. Cardinal Health reported EPS of $1.84, which beat the consensus analyst estimates for $1.74 by 10 cents. Its non-GAAP operating earnings rose 14% to $605 million. Segment profit increases in the Global Medical Products and Distribution and Pharmaceuticals and Specialty Solutions segments primarily drove the growth. Revenues grew 12.1% YoY to $59.87 billion, which also beat the consensus analyst estimate of $58.74 billion.
Fiscal 2024 operating cash flow and adjusted free cash flow reached all-time highs of $3.8 billion and $3.9 billion, respectively. Fiscal full-year 2024 revenues rose 11% YoY to $226.8 billion. Full-year non-GAAP diluted EPS rose 29% to $7.53.
<h2>Cardinal Health Raises Its Guidance </h2>
The company issued upside fiscal full-year 2025 non-GAAP EPS of $7.55 to $7.70 versus $7.53 consensus estimates, raising it from previous guidance of $7.50. Full-year revenue is expected to grow 10% to 12% YoY. Its Pharmaceutical and Specialty Solutions segment is expected to see revenues decline 4% to 6% YoY. Its Global Medical Products and Distribution (GMPD) segment is expected to see 3% to 5% revenue growth. Other revenue is expected to grow 10% to 12% YoY.
Cardinal Health CEO Jason Hollar commented, &quot;We delivered robust cash flow generation, continued profit growth in the Pharmaceutical and Specialty Solutions segment and significant improvement driven by our GMPD Improvement Plan. We enter the new fiscal year with momentum and confidence, evidenced by our raised fiscal year 2025 guidance.&quot;
CAH analyst ratings and price targets are at MarketBeat. There are 12 analyst ratings on CAH stock, comprised of seven Buys, two Holds, and one Sell. Consensus analyst price targets point to a 7% upside at $117.45.
The article &quot;<a href="https://www.nasdaq.com/articles/cardinal-health-soars-americas-leading-acute-care-supplier">Cardinal Health Soars as America&#39;s Leading Acute Care Supplier</a>&quot; first appeared on MarketBeat.

Cardinal Health Soars as America's Leading Acute Care Supplier

JP Morgan analyst Lisa Gill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Neutral and raises the price target from $111 to $123.

JP Morgan Maintains Neutral on Cardinal Health, Raises Price Target to $123

Cardinal Health Announced That Its Plans To Open A New Distribution Center In Walton Hills, Ohio, Supporting Its U.S. Medical Products And Distribution Business

Deutsche Bank analyst George Hill maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Hold and raises the price target from $115 to $119.

Deutsche Bank Maintains Hold on Cardinal Health, Raises Price Target to $119

Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) has outperformed the market over the past 5 years by 6.06% on an annualized basis producing an average annual return of 19.81%. Currently, Cardinal Health has a market capitalization of $26.35 billion. 
Buying $1000 In CAH: If an investor had bought $1000 of CAH stock 5 years ago, it would be worth $2,485.05 today based on a price of $108.05 for CAH at the time of writing.
<h3>Cardinal Health's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723820577_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cardinal Health Stock In The Last 5 Years

UBS analyst Kevin Caliendo maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Buy and raises the price target from $120 to $125.

UBS Maintains Buy on Cardinal Health, Raises Price Target to $125

Wells Fargo analyst Stephen Baxter maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Underweight and raises the price target from $95 to $101.

Wells Fargo Maintains Underweight on Cardinal Health, Raises Price Target to $101

Morgan Stanley analyst Erin Wright maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Overweight and raises the price target from $114 to $119.

Morgan Stanley Maintains Overweight on Cardinal Health, Raises Price Target to $119

Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/news/earnings/24/08/40364087/pharma-distribution-giant-cardinal-health-lifts-2025-guidance-after-q4-earnings-beat-raises-stock-b">fourth quarter on Wednesday.</a>
Cardinal Health reported fourth-quarter 2024 adjusted EPS of $1.84, up 29% year over year, beating the consensus of $1.73.
Sales increased 12% to $59.87 billion, beating the consensus of $58.64 billion. The pharmaceutical segment revenue increased 12% to $55.6 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.
Cardinal Health raised its fiscal year 2025 adjusted EPS guidance to $7.55-$7.70 from the preliminary outlook of at least $7.50 versus the consensus of $7.53.
The company updated its Pharmaceutical and Specialty Solutions segment profit growth outlook to 1%-3% growth from at least 1%. For the Global Medical Products and Distribution segment, the company expects revenue growth of 3%-5%. Overall revenue is expected to grow between 10%-12%.
"We enter the new fiscal year with momentum and confidence, evidenced by our raised fiscal year 2025 guidance," said Jason Hollar, CEO of Cardinal Health.
Cardinal Health shares closed at $106.36 on Wednesday.
These analysts made changes to their price targets on Cardinal Health following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> maintained Cardinal Health with an Outperform and raised the price target from $130 to $137.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5ece538c4a1e100001de8a1a/elizabeth-anderson">Evercore ISI Group analyst Elizabeth Anderson</a> maintained Cardinal Health with an In-Line and boosted the price target from $105 to $115.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40393013/pfizer-conagra-brands-and-2-other-stocks-insiders-are-selling">Pfizer, Conagra Brands And 2 Other Stocks Insiders Are Selling</a></li>
</ul>
Considering buying CAH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="574" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-1024x574.png" alt="" class="wp-image-496733" style="width:414px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-1024x574.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15084048/image-1-38.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Evercore ISI Group analyst Elizabeth Anderson maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a In-Line and raises the price target from $105 to $115.

Evercore ISI Group Maintains In-Line on Cardinal Health, Raises Price Target to $115

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our a<a href="https://www.benzinga.com/analyst-stock-ratings">nalyst ratings page.</a>
<ul>
<li>Rosenblatt raised the price target for Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) from $65 to $69. Rosenblatt analyst Mike Genovese maintained a Buy rating. Lumentum shares fell 1.5% to close at $45.53 on Wednesday. <a href="https://www.benzinga.com/quote/LITE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased the price target for The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from $250 to $252. Piper Sandler analyst Paul Newsome maintained an Overweight rating. Progressive shares gained 5.4% to close at $234.34 on Wednesday. <a href="https://www.benzinga.com/quote/PGR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. cut Century Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) price target from $11 to $9. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Century Therapeutics shares fell 5.5% to close at $1.56 on Wednesday. <a href="https://www.benzinga.com/quote/IPSC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from $200 to $130. Wells Fargo analyst Michael Turrin downgraded the stock from Overweight to Equal-Weight. Snowflake shares gained 0.2% to close at $127.30 on Wednesday. <a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt boosted Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) price target from $56 to $58. Rosenblatt analyst Mike Genovese maintained a Neutral rating. Cisco shares gained 0.2% to close at $45.44 on Wednesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs increased The Allstate Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) price target from $199 to $204. Goldman Sachs analyst Alex Scott maintained a Buy rating. Allstate shares gained 5.2% to close at $180.95 on Wednesday. <a href="https://www.benzinga.com/quote/ALL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS increased the price target for Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) from $76 to $90. UBS analyst Danielle Antalffy upgraded the stock from Sell to Neutral. Medtronic shares fell 0.6% to close at $81.74 on Wednesday.<a href="https://www.benzinga.com/quote/MDT/analyst-ratings"> See how other analysts view this stock.</a></li>
<li>Citigroup cut Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) price target from $170 to $155. Citigroup analyst Asiya Merchant maintained a Buy rating. Dell shares gained 3% to close at $102.95 on Wednesday. <a href="https://www.benzinga.com/quote/DELL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) price target from $130 to $137. Baird analyst Eric Coldwell maintained an Outperform rating. Cardinal Health shares rose 3.7% to close at $106.36 on Wednesday. <a href="https://www.benzinga.com/quote/CAH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank boosted Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) price target from $21 to $24. Deutsche Bank analyst Brian Bedell upgraded the stock from Hold to Buy. Robinhood shares gained 1.3% to close at $18.65 on Wednesday. S<a href="https://www.benzinga.com/quote/HOOD/analyst-ratings">ee how other analysts view this stock.</a></li>
</ul>
Read Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/08/40368892/jim-cramer-avoid-middle-market-plays-like-golub-capital-buy-mueller-industries-it-is-fan">Jim Cramer: &#8216;Avoid Middle Market Plays&#8217; Like Golub Capital, Buy Mueller Industries — &#8216;It Is Fantastic&#8217;</a></li>
</ul>
Considering buying Robinhood stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-1024x571.png" alt="" class="wp-image-496664" style="width:511px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/15080944/image-115.png 1240w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Pre-Market Outlook

CSCO

DELL

HOOD

IPSC

LITE

SNOW

Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday

Baird analyst Eric Coldwell maintains Cardinal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) with a Outperform and raises the price target from $130 to $137.

Baird Maintains Outperform on Cardinal Health, Raises Price Target to $137

The July consumer inflation report released Wednesday confirmed a continued cooling trend in price increases across the economy, with the headline Consumer Price Index (CPI) coming in at 2.9% year-over-year, slightly below both the <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40365730/july-inflation-rate-falls-more-than-expected-supports-hopes-for-large-fed-rate-cu">previous and expected 3%. </a>
Core inflation, which excludes food and energy, also saw a modest decline from 3.3% to 3.2% year-over-year, aligning with economists&#8217; forecasts.
For investors, this signals that the Federal Reserve may have the green light to cut interest rates in September. However, the odds of a 25 basis point hike are slightly higher than those of a 50 basis point cut.
Wall Street had a mixed response to the data. Major indices initially rose around 10 a.m. E.T. before flattening out by midday trading in New York.
Both S&amp;P 500 and Nasdaq 100 are striving to secure their fifth consecutive sessions in the green.
Financial stocks outperformed among the 11 sectors of the S&amp;P 500. The biggest laggards were communication services, weighed down by a decline in Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), and consumer discretionary, dragged by Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Starbucks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>).
Long-dated Treasury yields fell by 4 basis points, boosting the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) by 0.6%.
The U.S. dollar index, as tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), remained steady, while gold eased by 1%.
Oil prices, tracked by the United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>), declined by 1.1%, marking the second consecutive session of losses.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dropped 2.4% to $59,100.
<h1 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,894.49</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,442.32</td>
<td>0.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>18,967.78</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,081.22</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was 0.1% higher to $542.64.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.4% to $399.25.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) eased 0.1% to $461.91.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) tumbled 0.9% to $206.01.</li>
<li>The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, up by 0.8%. The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) lagged, down by 0.8%.</li>
</ul>
<h1 class="wp-block-heading">Wednesday&#8217;s Stock Movers</h1>
<ul>
<li>Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) surged 7.7% after the company announced it would be acquired by Mars in an all-cash deal valued at $35.9 billion.</li>
<li>Alphabet Inc. fell nearly 3% after reports that the U.S. Department of Justice may break up Google following a recent ruling that it monopolized the online search market.</li>
<li>Charles Schwab Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) jumped over 4% after reporting that total client assets reached $9.572 trillion in July, up 16% year-over-year and 2% from June, with core net new assets surging 112% to $29 billion compared to July 2023.</li>
<li>Other financial stocks marking strong gains on Wednesday included The Allstate Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>), The Progressive Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) and Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) up 5%, 4.8% and 3.2%, respectively.</li>
<li>Stocks moving on earnings report were Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 4%, Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>), down 14% and Performance Food Group Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) up 8%. </li>
<li>Those reporting after the close include Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) and Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>).</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40370641/mortgage-applications-rocket-by-16-8-notch-strongest-weekly-increase-in-1-5-years-homebuyers-too">Mortgage Applications Rocket By 16.8%, Notch Strongest Weekly Increase In 1.5 Years: &#8216;Homebuyers Took The Opportunity To Refinance&#8217;</a></li>
</ul>
This photo was created using artificial intelligence MidJourney.

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Treasuries

Econ #s

Economics

Tech

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

GOOG

GOOGL

PFGC

SBUX

SCHW

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

PowerShares DB US Dollar Index Bullish Fund

Select Sector SPDR-Consumer Discretionary

Wall Street Battles For Fifth Day Of Gains As Inflation Cools, Gives Green Light To Rate Cuts; Financials Outperform: What's Driving Markets Wednesday?

The July Consumer Price Inflation report made another step toward the Federal Reserve&#8217;s 2% target, though less pronounced than June&#8217;s, sustaining optimism for <a href="https://www.benzinga.com/topic/inflation">imminent interest rate cuts.</a>
Last month, a basket of goods and services purchased by U.S. consumers rose by 2.9% year-over-year, slightly below the previous and expected 3%, marking the fourth consecutive decline in annual inflation and the <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40365730/july-inflation-rate-falls-more-than-expected-supports-hopes-for-large-fed-rate-cu">lowest rate since March 2021.</a>
The annual core inflation rate also eased as anticipated, from 3.3% to 3.2%, the lowest since April 2021. 
However, the July report was marred by an increase in the shelter component, which, due to its significant weight in the basket, accounted for about 90% of the headline inflation rise.
The decline in annual inflation rates wasn&#8217;t sufficient to bolster expectations for a 50-basis-point rate cut in September. 
Market-implied probabilities for such a substantial cut dropped from 50% to 43% following the report, while the likelihood of a smaller 25-basis-point cut increased to 57%.
<h3 class="wp-block-heading">Market Reactions: Stocks Rise, Yields Steady, But Dollar Strengthens Against Yen</h3>
The July inflation data sparked a positive reaction in stocks, especially in the tech sector, with small caps outperforming their larger-cap counterparts. Treasury yields remained largely stable, while the U.S. dollar gained ground against the low-yielding Japanese yen.
Here are the premarket price reactions of the following exchange-traded funds (ETFs) to the inflation data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.2% at 09:10 a.m. in New York. Major premarket gainers were Kellanova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/K#NYSE">K</a>) and Cardinal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), up 7.2% and 5.5% respectively. </li>
<li>The tech-heavy Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.3%. Top gainers were Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) and Micron Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) up 3.1% and 3%, respectively. </li>
<li>Semiconductors were the strongest-performing industry, with the VanEck Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NYSE">SMH</a>) up 0.9%. Micron Technology Inc. and ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) led gains, with the latter up 2.1%. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 0.5%, with Victoria&#8217;s Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) and AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) making the larger gains in the premarket, up 16% and 13%, respectively. </li>
<li>The Invesco CurrencyShares Japanese Yen Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXY#NYSE">FXY</a>) fell 0.2%.</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/08/40355203/stocks-now-dismiss-recession-fears-but-bond-markets-tell-investors-to-stay-on-alert">Stocks Now Dismiss Recession Fears, But Bond Markets Tell Investors To Stay On Alert</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Small Cap

Federal Reserve

ANAB

ASML

VSCO

S&P 500 Rises, Small Caps Outperform As July Consumer Price Index Fuels Fed Rate Cut Hopes: 5 ETFs to Watch Wednesday

As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>)</h3>
<ul>
<li>On Aug. 14, Cardinal Health posted better-than-expected quarterly results. &#8220;Fiscal 2024 marked a year of strong operational execution and record financial results, delivered in tandem with key strategic progress in the portfolio,&#8221; said Jason Hollar, CEO of Cardinal Health. The company's stock gained around 9% over the past month and has a <a href="https://www.benzinga.com/quote/CAH">52-week high of $116.04</a>.</li>
<li>RSI Value: 72.55&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CAH Price Action: Shares of Cardinal Health gained 1.9% to close at $102.58 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Catalyst Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>)</h3>
<ul>
<li>On Aug. 7, Catalyst Pharmaceuticals reported better-than-expected second-quarter financial results. &#8220;Since the onset of this year, we have advanced with continued momentum, propelled by the strong performance of our established product portfolio and the successful U.S. commercial launch of AGAMREE. Our accomplishments have significantly strengthened our financial position, aligning with our revenue guidance for the year, and we believe that we are on track to achieve the upper end of our previously provided total revenue forecast,&#8221; stated Richard J. Daly, President and CEO of Catalyst. The company's stock gained around 19% over the past five days and <a href="https://www.benzinga.com/quote/CPRX">has a 52-week high</a> of $19.86.</li>
<li>RSI Value: 73.73</li>
<li>CPRX Price Action: Shares of Catalyst Pharmaceuticals gained 1.5% to close at $19.59 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Verona Pharma PLC &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>)</h3>
<ul>
<li>On Aug. 8, Verona Pharma posted a narrower-than-expected quarterly loss. &#8220;We are very pleased today to announce that Ohtuvayre (ensifentrine) is now available in the US for the maintenance treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;) in adults,&#8221; said David Zaccardelli, Pharm. D., President and Chief Executive Officer. The company's stock gained around 26% over the past five days and has a <a href="https://www.benzinga.com/quote/VRNA">52-week high</a> of $28.26.</li>
<li>RSI Value: 71.22</li>
<li>VRNA Price Action: Shares of Verona Pharma gained 8.3% to close at $26.73 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40357992/brinker-international-cisco-and-3-stocks-to-watch-heading-into-wednesday">Brinker International, Cisco And 3 Stocks To Watch Heading Into Wednesday</a></li>
</ul>

Short Ideas

CPRX

VRNA

Top 3 Health Care Stocks That May Crash In August

Wednesday, Cardinal Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>) reported fourth-quarter 2024 adjusted EPS of $1.84, up 29% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.73</a>.
Cardinal Health is&nbsp;a distributor of pharmaceuticals, a manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40357895/cardinal-health-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-a" rel="noreferrer noopener">for healthcare facilities</a>.
Sales increased 12% to $59.87 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/n40361087/cardinal-health-reports-fourth-quarter-and-fiscal-year-2024-results-and-raises-fiscal-year-2025-gu" rel="noreferrer noopener">consensus of $58.64 billion</a>.
The pharmaceutical segment revenue increased 12% to $55.6 billion, driven by brand and specialty pharmaceutical sales growth from existing customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38356630/drug-distributing-giant-cardinal-health-will-not-renew-optumrx-distribution-pact-stock-plunges" rel="noreferrer noopener">Drug Distributing Giant Cardinal Health Will Not Renew OptumRx Distribution Pact, Stock Plunges</a>.
Medical segment revenue increased by 2% to $3.1 billion, driven by volume growth from existing customers.
Cardinal Health reiterated its fiscal year 2026 target of approximately&nbsp;$300 million&nbsp;in Global Medical Products and Distribution (GMPD) segment profit.
Additionally, by fiscal year 2026, the company is targeting at least&nbsp;$500 million&nbsp;in near-term value creation from GMPD through further simplification actions and working capital improvements, with the cash to be deployed according to its disciplined capital allocation framework.
Therefore, the company is raising its share repurchase expectations in fiscal year 2025 by&nbsp;$250 million&nbsp;to $750 million.
Outlook:&nbsp;Cardinal Health raised its fiscal year 2025 adjusted EPS guidance to $7.55-$7.70 from the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38576744/cardinal-health-reports-third-quarter-fiscal-year-2024-results-and-raises-fiscal-year-2024-non-gaa" rel="noreferrer noopener">preliminary outlook of at least $7.50</a> versus the consensus of $7.53.
The company updated its Pharmaceutical and Specialty Solutions segment profit growth outlook to 1%-3% growth from at least 1%.
For the Global Medical Products and Distribution segment, the company expects revenue growth of 3%-5%. Overall revenue is expected to grow between 10%-12%.
&#8220;We enter the new fiscal year with momentum and confidence, evidenced by our raised fiscal year 2025 guidance,&#8221; said&nbsp;Jason Hollar, CEO of Cardinal Health.
Price Action: At last check on Wednesday, CAH stock was up 5.14% at $107.85 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40348867/struggling-covid-19-vaccines-from-astrazeneca-biontechpfizer-moderna-cut-incidence-of-arterial-th" target="_blank" rel="noreferrer noopener">Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows</a>.</li>
</ul>
Photo via Company

Buybacks

Movers

Pharma Distribution Giant Cardinal Health Lifts 2025 Guidance After Q4 Earnings Beat, Raises Stock Buyback Expectation By $250M

WIIM

Cardinal Health shares are trading higher after the company reported strong Q4 results and raised its 2025 outlook.

The major index futures are pointing to a nervous start ahead of the <a href="https://www.benzinga.com/etfs/sector-etfs/24/08/40323092/feds-interest-rate-decision-will-incoming-july-inflation-data-tip-the-scale">consumer price inflation report </a>that is due at 8:30 a.m. EDT. Bond yields are slipping ahead of the inflation data. If the report confirms a continued let-up in pricing pressure, the Federal Reserve may be forced to cut rates. Economists and strategists expect Fed Chair Jerome Powell to render more clarity on the rate outlook at the Jackson Hole symposium scheduled for later this month.
Atlanta Federal Reserve President Raphael Bostic, however, suggested he would want to see more evidence before the rate could be taken down from its 22-year high. 
Hon Hai Precision Industry Co. Ltd.&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HNHPF#OTC">HNHPF</a>) commentary about strong AI server demand could lend support to Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and other AI-levered tech stocks. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>+0.07%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>+0.05%</td>
</tr>
<tr>
<td>Dow</td>
<td>+0.01%</td>
</tr>
<tr>
<td>R2K</td>
<td>+0.44%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption"> In premarket trading on Wednesday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) edged up 0.06% to $542.34, and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.05% to $462.81, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.</figcaption></figure>
Cues From Last Session: 
Stocks raced out of the gate on Tuesday after a tamer-than-expected producer price inflation report perked up risk appetite. The VIX at one point in time pulled back below the 18 level. All three major averages opened higher and advanced further over the course of trading before ending notably higher. The tech-heavy Nasdaq Composite and the S&amp;P 500 indices closed at their highest levels since Aug. 1. In the process, the S&amp;P 500 posted the biggest four-day rally for the year. 
Technical analyst and CNBC contributor Frank Cappelleri noted that the S&amp;P 500 has advanced 4.8% over six sessions, the best six-day gain since the 6% rise between Oct. 30, 2023 and Nov. 6, 2023.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SPX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPX</a> The 6-day advance now is +4.8%. That&#39;s the best since the 6-day gain of +6.0% from 10/30-11/6/23. The index is now challenging its 50-DMA and a key downtrend line… …which ALSO is similar to early Nov'23. <a href="https://t.co/mTvo9TBu7H">pic.twitter.com/mTvo9TBu7H</a>
&mdash; Frank Cappelleri (@FrankCappelleri) <a href="https://twitter.com/FrankCappelleri/status/1823474564686627315?ref_src=twsrc%5Etfw">August 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>+2.43%</td>
<td>17,187.61</td>
</tr>
<tr>
<td>S&amp;P 500 Index</td>
<td>+1.68%</td>
<td>5,434.43</td>
</tr>
<tr>
<td>Dow Industrials</td>
<td>+1.04%</td>
<td>39,765.64</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>+1.61%</td>
<td>2,095.19</td>
</tr>
</tbody>
</table>
</figure>
 Insights From Analysts:
Commenting on the market recovery post-Monday&#8217;s meltdown, fund manager Louis Navellier said, &#8220;Barring any major geopolitical surprises, it appears likely that the recovery from the recent correction will continue, though with caution rather than the strong melt-ups we&#8217;ve seen this year.&#8221;
&#8220;The NVIDIA earnings on Aug. 28 will be pivotal to a full recovery,&#8221; he said.  
Upcoming Economic Data:
The July consumer price inflation report is the lone piece of first-tier data due on Wednesday. Here&#8217;s how the expectations compare to the prior periods:
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td></td>
<td>Consensus</td>
<td>June Performance</td>
</tr>
<tr>
<td>Consumer Prices (M-o-M)</td>
<td>+0.2%</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Consumer Prices (Y-o-Y)</td>
<td>+3.0%</td>
<td>+3.0%</td>
</tr>
<tr>
<td>Core consumer prices (M-o-M)</td>
<td>+0.2%</td>
<td>+0.1%</td>
</tr>
<tr>
<td>Core consumer prices (Y-o-Y)</td>
<td>+3.2%</td>
<td></td>
</tr>
</tbody>
</table>
</figure>
The Energy Information Administration will release its weekly petroleum status report at 10:30 a.m. EDT.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Stocks In Focus:
<ul>
<li>Peloton Interactive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) climbed nearly 7% <a href="https://www.benzinga.com/premarket">in premarket trading</a> after the company announced a content partnership with Alphabet, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Fitbit.</li>
<li>Kellanova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/K#NASDAQ">K</a>) rose about 6.50% after the Wall Street Journal reported Mars, Inc. is nearing a deal to buy the former.</li>
<li>Cardinal Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) and Performance Food Group Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) are among the <a href="https://www.benzinga.com/calendars/earnings">notable companies reporting earnings ahead of the market open.</a></li>
<li>Those reporting after the close include Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) and Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>).</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures edged down, signaling that the black gold may extend the 2%+ drop seen in the previous session, and gold futures rose modestly. The 10-year Treasury- note yield slipped 1.7 basis points to 3.837%. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continued its climb and traded above the $61K level.
The Asian markets advanced, as traders cheered Wall Street&#8217;s buoyant performance overnight and began to price in a Fed rate cut. The Chinese and Hong Kong markets, however, bucked the uptrend. European stocks were modestly higher in early trading, with UBS AG&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) lending support to financial stocks.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40359306/kevin-oleary-calls-kamala-harris-show-me-story-elon-musk-modern-day-bruce-wayne-shark-tank-star-disc">Kevin O&#8217;Leary Calls Kamala Harris&#8217; &#8216;Show-Me&#8217; Story, Elon Musk &#8216;Modern Day Bruce Wayne:&#8217; &#8216;Shark Tank&#8217; Star Discusses Inflation And Market Opportunity</a></li>
</ul>
Image Via Shutterstock

Futures

Previews

HNHPF

NVDA

PTON

Wall Street Set For Subdued Start As Traders Await All-Important Inflation Data, Bitcoin Tops $61K: Fund Manager Flags This Event As Pivotal To Near-term Market Recovery

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Pharmaceutical and Specialty Solutions segment:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">4% to 6% decline5</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment profit</td>
<td colspan="1" rowspan="1">1% to 3% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Global Medical Products and Distribution segment:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">3% to 5% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment profit</td>
<td colspan="1" rowspan="1">~$175M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other:</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">10% to 12% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment profit</td>
<td colspan="1" rowspan="1">~10% growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest and other</td>
<td colspan="1" rowspan="1">$140M - $170M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP effective tax rate</td>
<td colspan="1" rowspan="1">23.0% - 24.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted weighted average shares outstanding</td>
<td colspan="1" rowspan="1">~243M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Share repurchases</td>
<td colspan="1" rowspan="1">$750M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital Expenditures</td>
<td colspan="1" rowspan="1">$500M to $550M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP adjusted free cash flow</td>
<td colspan="1" rowspan="1">~$1.0B6</td>
</tr>
</tbody>
</table>
</figure>

Cardinal Health Raised Its Fiscal Year 2025 Outlook For Adjusted EPS To $7.55-$7.70 From The Preliminary Outlook Of At Least $7.50 Versus Consensus Of $7.53

Mizuho Securities analyst Ann Hynes has reiterated their neutral stance on CAH stock, giving a Hold rating yesterday. Ann Hynes has given his Hold ...

Balancing Act: Hold Rating Amid Cardinal Health's Strong Performance and Future Uncertainties

Cardinal Health declares $0.5056 dividend

Several companies have stolen the spotlight throughout the earnings period, including Walmart, Cardinal Health, and Eli Lilly. All three posted robust results and upped guidance, as shares of each experienced bullish activity post earnings.

3 Companies Reporting Remarkable Results: Walmart, Eli Lilly, Cardinal Health

Goldman Sachs' favorite mutual funds positions that are overweight the Russell 1000

Bert's July Dividend Income Summary (2024)

The stock market as measured by the S&P is currently at an all-time high which makes it very challenging to try to build a quality dividend growth portfolio.

How To Build A Dividend Growth Portfolio In An Overpriced Market

Cardinal Health Q4 Earnings: FY25 Is A Short-Term Blip

Medical distributors, health plans ink $300M opioid settlement

Cardinal Health (CAH) Morgan Stanley 22nd Annual Global Healthcare Conference Transcript

Cardinal Health ( ($CAH) ) has shared an update. Cardinal Health, Inc. board members Steven K. Barg and Sujatha Chandrasekaran, both appointed in 2...

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Comments

Cardinal Health

Cardinal Health (CAH) Forecast

Cardinal Health (NYSE:CAH) Stock, Quote.Headers.trade-ideas